Prelude Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	270	234	289	588	3,127	-
Market Cap Growth	-	-19.01%	-50.82%	-81.20%	-	-
Enterprise Value	50	14	85	294	2,909	-19
PE Ratio	-1.92	-1.92	-2.50	-5.26	-54.93	-
PB Ratio	1.14	0.99	1.48	2.06	14.74	-
P/FCF Ratio	-2.12	-2.12	-3.33	-6.85	-66.82	-
P/OCF Ratio	-2.19	-2.19	-3.45	-7.04	-67.72	-
EV/EBITDA Ratio	-0.12	-0.12	-0.76	-2.69	-51.58	0.68
EV/EBIT Ratio	-0.12	-0.12	-0.74	-2.63	-51.09	0.68
EV/FCF Ratio	-0.13	-0.13	-0.98	-3.43	-62.15	0.70
Debt / Equity Ratio	0.07	0.07	0.01	0.01	-	-0.01
Debt / EBITDA Ratio	-0.14	-0.14	-0.02	-0.02	-	-0.01
Debt / FCF Ratio	-0.15	-0.15	-0.02	-0.02	-	-0.01
Quick Ratio	10.86	10.86	9.48	15.38	19.19	3.90
Current Ratio	10.79	10.79	9.42	15.37	19.41	4.18
Return on Equity (ROE)	-53.40%	-53.40%	-50.40%	-34.70%	-69.90%	76.50%
Return on Assets (ROA)	-48.00%	-48.00%	-46.10%	-33.00%	-46.40%	-144.10%
Return on Capital (ROIC)	-52.08%	-52.08%	-62.63%	-39.54%	-27.69%	57.19%
Earnings Yield	-45.06%	-52.04%	-39.93%	-19.00%	-1.82%	-
FCF Yield	-40.89%	-47.23%	-30.01%	-14.61%	-1.50%	-
Buyback Yield / Dilution	-27.41%	-27.41%	-2.87%	-269.03%	-647.86%	-2.83%
Total Shareholder Return	-27.41%	-27.41%	-2.87%	-269.03%	-647.86%	-2.83%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).